Cholestasis clinical trials at UC Davis
1 research study open to eligible people
Studying Doses of Experimental GSK2330672 for Pruritus (itch) in Patients With Primary Biliary Cholangitis (damaged bile ducts)
“This study drug is intended for the treatment of pruritus (itch) in participants with primary biliary cholangitis (PBC).”
open to eligible people ages 18-80
This study is being conducted to evaluate the efficacy, safety and tolerability of GSK2330672 administration for the treatment of pruritus (itch) in participants with primary biliary cholangitis (PBC). Participants will be treated with either placebo or one of the 4 dose regimens of GSK2330672 (20 milligram [mg], 90 mg or 180 mg taken once daily or 90 mg twice daily). Subjects on GSK2330672 will also receive placebo tablets to maintain blinding. The total duration of a subject's participation will be up to 45 days of screening and 24 weeks of study including follow-up.
Sacramento, California and other locations